PONTCHARTRAIN CANCER CENTER CLINICAL TRIALS
+ About Our Research Program
Pontchartrain Cancer Center has been participating in clinical research since January 2016. We offer several Phase 2, 3, and 4 trials in different disease indications at both practice locations (Covington and Hammond). Our current clinical trials are listed below.
What Makes Our Site Unique?
- Central IRB only
- Complete study start-up takes 4-6 weeks (contract/budget, regulatory, SIV, etc.)
- Certified Clinical Research Coordinator (2 coordinators total)
If you are interested in learning more about clinical research studies at PCC, contact Chelsea McKean, our Director of Research, at (985) 888-1523 or email email@example.com.
+ What is Clinical Research
Clinical research trials are studies that determine the safety and effectiveness of new drugs, devices, or treatment regimens. Each clinical trial is designed to discover new or improved ways of treating cancer. Patients who participate in clinical trials help physicians and future cancer patients determine whether a treatment is safe and effective.
Before a patient is enrolled in a clinical research trial, studies must be approved by an Institutional Review Board (IRB), or an independent ethics committee. This entity assures the appropriate steps are taken to protect the well-being of research participants. All patients who participate in clinical trials are carefully monitored throughout the study, and typically for several months after the trial has ended, to determine safety of the treatment being tested. It is important to remember that clinical trials are completely voluntary, and patients can withdraw from a trial at any time.
+ Why Participate in Clinical Research?
Enrollment of patients in clinical trials is essential for progress in conquering cancer. While nationwide, only 6% of cancer patients participate in clinical trials, we are proud to announce that in our community, 15% of patients do so. When considering participating in clinical research trials, patients must learn about the benefits and risks like they would when receiving any standard treatment for their cancer. Some of the benefits of participating in clinical trials: Gain access to new research treatments before they are widely available
- Access to study-required medical care at no cost
- Close attention from your study team such as follow-ups regarding your care
- Play a more active role in your healthcare
- Opportunity to participate in research that may potential benefit others
However, participation in clinical trials can require greater time commitment as there may be more tests and visits to the clinic. Clinical trial participants may also experience unpleasant, serious, or life-threatening side effects, and your condition may not improve. Therefore, it is important to discuss if a clinical trial is right for you with your provider.
OUR CLINICAL RESEARCH
Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
ESSENTIAL THROMBOCYTHEMIA AND MYELOFIBROSIS
A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients ≥18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy
A randomized parallel group phase III trial of OSE2101 as 2nd or 3rd line compared with standard treatment (docetaxel or pemetrexed) in HLA-A2 positive patients with locally advanced (IIIB) unsuitable for radiotherapy or metastatic (IV) Non-Small-Cell Lung Cancer
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™
A Two-Stage, Open-Label Followed by Placebo-Controlled Phase 2 Study of Pracinostat and Azacitidine in Patients With IPSS-R High and Very High Risk Myelodysplastic Syndromes Previously Untreated With Hypomethylating Agents